Drug intelligence / Profile preview

palbociclib + 5-fluorouracil + oxaliplatin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination therapy consists of the CDK4/6 inhibitor palbociclib (PD-0332991), the antimetabolite 5-fluorouracil (5-FU), and the platinum-based chemotherapy agent oxaliplatin. Evaluated in a Phase I clinical trial (NCT01522989) led by Georgetown University, the regimen targets advanced solid tumor malignancies. Palbociclib works by selectively inhibiting cyclin-dependent kinases 4 and 6, which arrests the cell cycle in the G1 phase and potentially sensitizes cancer cells to cytotoxic agents. 5-fluorouracil acts as a thymidylate synthase inhibitor to disrupt DNA synthesis, while oxaliplatin forms DNA cross-links that inhibit replication and transcription. The combination aims to leverage the synergistic effects of targeted cell cycle inhibition and standard cytotoxic chemotherapy to improve outcomes in patients with advanced cancers.

Brand names: IbranceAdrucilEloxatin
Other names: Keytruda-Georgetown University-advanced solid tumor malignanciesPD-0332991 + 5-FU + OxaliplatinPalbociclib + 5-Fluorouracil + Oxaliplatin

Targets

DNACDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)TS (Thymidylate synthase)

Beyond the preview

Go deeper on palbociclib + 5-fluorouracil + oxaliplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on palbociclib + 5-fluorouracil + oxaliplatin.

Explore the full profile